SCOTUS to review Purdue bankruptcy settlement; Pfizer to halt development of its twice-daily oral obesity drug

Taking stock of the drug industry, from the lab to the medicine chest

December 1, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Toby Talbot/AP STAT+ | U.S. Supreme Court to review controversial Purdue Pharma bankruptcy settlement Purdue Pharma is accused of downplaying OxyContin risks. Its owners, the Sackler family, would contribute $6 billion in exchange for immunity. By Ed Silverman STAT+ | Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial Pfizer said it was stopping development of a twice-daily oral obesity medication, a blow to the company's efforts to compete in the booming field.   By Andrew Joseph and Elaine Chen Johnson & Johnson bets heavy on AI-driven drug discovery Today's biotech news updates include Pfizer's obesity woes, how J&J is leaning heavily into artificial intelligence, and the zombie microcap. By Meghana Keshavan Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT+ | Senate Republicans throw cold water on so-called site-neutral hospital pay cuts House Republicans want to use a small cut to hospitals' Medicare payments to help finance a raft of health policy reforms. Senate Republicans aren't on board. By Rachel Cohrs

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser